Relapsed/refractory Ewing sarcoma prognosis is dreadful, especially for recurrences within the first 2 years after initial diagnosis. It is obvious that there is an urgent need for novel treatment strategies for this dismal situation. NK-92 is an activated NK cell line with high cytotoxicity against malignant cells. Here, we present a relapsed/refractory Ewing sarcoma case who had no response to conventional strategies and recieved intratumoral NK-92 cell injections. We observe that intratumoral injection of NK-92 is safe, has no toxicity and shows preliminary evidence of tumor response in relapsed/refractory Ewing Sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297928 | PMC |
| http://dx.doi.org/10.1007/s13691-020-00406-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board.
Cancer
December 2024
Department of Pediatric Hematology/Oncology/Bone Marrow Transplantation, Cleveland Clinic Children's, Cleveland, Ohio, USA.
Ewing sarcoma (ES) is a malignant tumor of bone and soft tissue that most often occurs in children, adolescents, and young adults. Debate and controversy remain in the management of relapsed/refractory ES (RR-ES). The authors leveraged the expertise assembled by the National Ewing Sarcoma Tumor Board, a multidisciplinary virtual tumor board that meets monthly to discuss challenging cases of ES.
View Article and Find Full Text PDFPurpose: Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216 was designed to bind EWS::FLI1 proteins directly, disrupt protein-protein interactions, and inhibit transcription factor function. TK216 plus vincristine showed synergistic activity in preclinical tumor models.
View Article and Find Full Text PDFHigh-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party.
Cancer Treat Rev
March 2024
Children's Cancer Centre, The Royal Children's Hospital Melbourne, VIC 3000, Australia; Department of Paediatrics, The University of Melbourne, Parkville VIC 3052 Australia; Murdoch Children's Research Institute, Melbourne, Australia.
Article Synopsis
- Patients with serious forms of Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) may benefit from a treatment called high-dose chemotherapy with stem cell transplant, but it's still unclear how much it helps and it can cause serious side effects.
- A review of many studies found that for some ES patients, this treatment can improve their chances of living longer compared to standard chemotherapy, especially if they receive it after a specific type of chemotherapy.
- However, for RMS patients and those with advanced ES, the evidence doesn't show a clear benefit, and more research is needed to understand the best treatment options.
Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study.
Clin Cancer Res
November 2023
Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, INSERM U1015, Université Paris-Saclay, Villejuif, France.
Article Synopsis
- A phase Ib study investigated the safety, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of regorafenib when combined with vincristine and irinotecan for treating kids with relapsed/refractory solid tumors, primarily rhabdomyosarcoma.
- The study involved 21 patients, determining the MTD/RP2D of regorafenib at 82 mg/m2 when given sequentially; adverse effects mostly included severe blood-related issues, with varying levels of response observed in tumors.
- Findings suggest that regorafenib can be safely combined with vincristine and irinotecan in pediatric settings, showing promising clinical activity for certain types of tumors.
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Pediatr Blood Cancer
August 2023
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Background: 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) can inhibit tumor proliferation, angiogenesis, and restore apoptosis in preclinical pediatric solid tumor models. We conducted a phase 1 trial to determine the maximum tolerated dose (MTD) of simvastatin with topotecan and cyclophosphamide in children with relapsed/refractory solid and central nervous system (CNS) tumors.
Methods: Simvastatin was administered orally twice daily on days 1-21, with topotecan and cyclophosphamide intravenously on days 1-5 of a 21-day cycle.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!